Loading patent…
AssigneeDuke University
InventorsJonathan S. Stamler, Claude A. Piantadosi, Mark W. Dewhirst
Estimating the term…
Patients with pathologic conditions involving constriction or proliferation of smooth muscle or disease associated with cysteine containing proteins, or who are at risk for such, are administered a therapeutically effective amount of a nitric oxide (NO) donor which is insufficient to acutely lower mean arterial blood pressure or pulmonary artery pressure by more than 10%. In one subgenus, NO donor is administered to modify red blood cell membrane receptors to prevent red blood cells from causing vasoconstriction. A related method which allows increased dosage of NO donor without acutely lowering mean arterial blood pressure comprises administering the NO donor into an artery of the patient. In another method, patients having a cardiovascular syndrome, or who are at risk for such, are administered a therapeutically effective amount of thiol which does not acutely affect blood pressure to a significant degree.
A method for prophylaxis or treatment of a patient with a disease of the vasculature involving constriction or proliferation of smooth muscle or other pathologic condition involving constriction or proliferation of smooth muscle, or at risk for such, except for acute thrombotic complications of restenosis or platelet embolism or other thromboembolic events, said method comprising administering to said patient an NO donor that donates nitric oxide or a related redox species and provides bioactivity that is identified with nitric oxide and which is capable of acutely lowering mean arterial blood pressure or pulmonary artery pressure by more than 10% in a therapeutically effective amount which is insufficient to acutely lower mean arterial blood pressure or pulmonary artery pressure by more than 10%, with the proviso that when the NO donor is ethyl nitrite, it is administered in a liquid, orally or by infusion.
A method for prophylaxis or treatment of a patient with a disease associated with a receptor having a cysteine residue or other cysteine containing protein that is modified by NO donor to inhibit its function, or at risk therefor, comprising administering to said patient an NO donor that donates nitric oxide or a related redox species and provides bioactivity that is identified with nitric oxide and which is capable of acutely lowering mean arterial blood pressure or pulmonary artery pressure by more than 10% in a therapeutically effective amount which is insufficient to acutely lower mean arterial blood pressure or pulmonary artery pressure more than 10%, with the proviso that when the NO donor is ethyl nitrite, it is administered in a liquid, orally or by infusion.
A method for treating a patient in need of an NO donor and increased blood pressure comprising administering a therapeutically effective amount of NO donor directly into an artery of the patient.
A method for the prophylaxis or treatment of a patient with a cardiovascular syndrome, or at risk therefor, comprising administering a therapeutically effective amount of a thiol which is insufficient to acutely lower mean arterial blood pressure or pulmonary artery pressure more than 10%.
Dependencies are inferred from the claim text.